Treatment of community-acquired lower respiratory tract infections in adults

European Respiratory Journal, Supplement

Volumn 20, Issue 36, 2002, Pages

  Örtqvist, Åke ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bacterial infection; Bronchitis; Lower respiratory tract infection; Pneumonia; Viral infection

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GREPAFLOXACIN; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEMAFLOXACIN; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BRONCHITIS; CONFERENCE PAPER; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; ADULT; BACTERIUM; COMMUNICABLE DISEASE; DRUG EFFECT; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOGENICITY; RESPIRATORY TRACT INFECTION; REVIEW;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX;

EID: 0036636829     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (100)

1. The management of infections and antibiotic therapy: A European survey
2. Antibiotic treatment of community-acquired pneumonia in clinical practice: A European perspective
3. Initial antibiotic therapy for lower respiratory tract infection in the community: A European survey
4. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures
5. Variation in antibiotic use in the European Union
6. Antimicrobial treatment of community-acquired pneumonia in adults: A conference report
7. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
8. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital
9. Management of adult community-acquired lower respiratory tract infections
10. Guidelines for management of adult community-acquired lower respiratory tract infections
11. Community-acquired pneumonia in adults: Guidelines for management
12. Practice guidelines for the management of community-acquired pneumonia in adults
13. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
14. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group
15. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention
16. Pneumonia and acute bronchitis
17. Lower respiratory tract infection and pneumonia in the community
18. Incidence of community-acquired pneumonia in the population of four municipalities in Eastern Finland
19. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis
20. The clinical features of severe community-acquired pneumonia presenting as septic shock
21. Quality of care, process, and outcomes in elderly patients with pneumonia
22. Use of investigations in lower respiratory tract infection in the community: A European survey
23. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians
24. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997)
25. Laboratory tests for pneumonia in general practice: The diagnostic values depend on the duration of illness
26. Akutt bronkitt hos voksne. Kliniske funn, mikroorganismer og bruk av antibiotika
27. C-reactive protein in simple community-acquired pneumonia
28. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia
29. Etiology of community-acquired pneumonia
30. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in Eastern Finland
31. Initial investigation and treatment of the patient with severe community-acquired pneumonia
32. Community-acquired pneumonia due to Chlamydia pneumoniae
33. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland
34. Treatment of community-acquired pneumonia
35. Community-acquired pneumonia: Initial management and empirical treatment
36. Community-acquired pneumonia: Development of a bedside predictive model and scoring system to identify the aetiology
37. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: Implications for management guidelines
38. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia
39. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: A randomized study of amoxicillin-clavulanate and ceftriaxone
40. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: Open, randomised controlled trial
41. Empirical therapy for nonhospitalized patients with community-acquired pneumonia
42. In-hospital management of adults who have community-acquired pneumonia
43. Implications for macrolide treatment in community-acquired pneumonia
44. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
45. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia
46. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia
47. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia
48. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin
49. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia
50. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia
51. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia
52. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults
53. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults
54. Pneumococcal pneumonia
55. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I - Results from the SENTRY Antimicrobial Surveillance Program (North America, 1998)
56. Penicillin dosing for pneumococcal pneumonia
57. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children
58. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae
59. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
60. Clinical outcome of invasive infections in children caused by highly penicillin-resistant Streptococcus pneumoniae compared with infections caused by penicillin-susceptible strains
61. Evolving resistance patterns of Streptococcus pneumoniae: A link with long-acting macrolide consumption?
62. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy
63. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
64. Fluoroquinolone resistance in Streptococcus pneumoniae
65. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
66. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin
67. Overwhelming pneumococcal pneumonia in a patient receiving ofloxacin for antimicrobial prophylaxis
68. Levofloxacin failure in a patient with pneumococcal pneumonia
69. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: A randomized, double-blind comparison with trovafloxacin
70. Linezolid - A review of the first oxazolidinone
71. Microbiological profile of telithromycin, the first ketolide antimicrobial
72. Community-acquired pneumonia: The evolving challenge
73. Severity prediction rules in community acquired pneumonia: A validation study
74. Defining prognostic factors in the elderly with community acquired pneumonia: A case controlled study of patients aged ≥ 75 yrs
75. A prediction rule to identify low-risk patients with community-acquired pneumonia
76. Applying a prediction rule to identify low-risk patients with community-acquired pneumonia
77. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria
78. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries
79. Treatment of acute bronchitis in adults without underlying lung disease
80. Antibiotics for acute bronchitis (Cochrane Review)
81. Management of acute exacerbations of COPD: A summary and appraisal of published evidence
82. The evidence base for management of acute exacerbations of COPD: Clinical practice guideline, part 1
83. Bacterial infection in chronic obstructive pulmonary disease in 2000: A state-of-the-art review
84. Antibody coating and quantitative cultures of bacteria in sputum and bronchial brush specimens from patients with stable chronic bronchitis
85. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients
86. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush
87. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis
88. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
89. Antimicrobial treatment failures in patients with community-acquired pneumonia: Causes and prognostic implications
90. Deaths in bacteremic pneumococcal pneumonia. A comparison of two populations - Huntington, WVa, and Stockholm, Sweden
91. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia
92. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
93. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997
94. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
95. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia
96. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia
97. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia
98. A prospective randomized study of inpatient i.v. antibiotics for community-acquired pneumonia. The optimal duration of therapy
99. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia